UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission FileNumber: 000-23143
PROGENICS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
One World Trade Center, 47th Floor Suite J
New York, New York
Tel: (646)975-2500
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Common stock, par value $0.0013 per share
(Title of each class of securities covered by this Form)
None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
| Rule12g-4(a)(1) | ☒ | |||
| Rule12g-4(a)(2) | ☐ | |||
| Rule12h-3(b)(1)(i) | ☒ | |||
| Rule12h-3(b)(1)(ii) | ☐ | |||
| Rule15d-6 | ☐ | |||
| Rule15d-22(b) | ☐ |
Approximate number of holders of record as of the certification or notice date: One.*
* On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated as of February 20, 2020, among Progenics Pharmaceuticals, Inc. (the “Company”), Lantheus Holdings, Inc. (“Parent”) and Plato Merger Sub, Inc. (“Merger Sub”), Merger Sub merged with and into the Company (the “Merger”), with the Company surviving the Merger as a subsidiary of Parent.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
Date: July 2, 2020
PROGENICS PHARMACEUTICALS, INC.
| ||
| By: | /s/ Daniel M. Niedzwiecki | |
| Name: | Daniel M. Niedzwiecki | |
| Title: | Secretary | |
